David LinetskyPoint-of-Care Marketing
Bud BilanichSuccess Coach
Daniel SontupeMarket Access
Liz KaneImpactful Strategy
Paul TheisenPatient Acquisition
Matt TurnerPatient Affordability
Pat PurcellMeeting Engagement
Joey CohenMedication Adherence
Amy GilesIncreasing Engagement
Suma Ramadas, PhDMedical Affairs
Frank BurrellScientific Storytelling
Stacey GandlerBrand Nourishment
Matthew DurhamOmnidynamic Marketing
Brenda SnowAuthentic Patient Voice
YELIVA®, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email